Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant dimeglumine injection for prevention of cisplatin-induced CINV
CTR20150598Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Hengrui Therapeutics. Started Oct 2015; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20150598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150598.